TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31484660

Group type: EXPERIMENTAL
Intervention: DFMO (500 mg orally) plus aspirin (325 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 27748986

Group type: EXPERIMENTAL
Intervention: Predictive model for cesarean delivery based on maternal characteristics
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Advanced maternal age, shorter maternal height, greater gestational age, perception of labor lasting more than 24 hours, mild or moderate contractions, less cervical dilation, and higher fetal station at time of hospital admission
Number of subjects: 1302
Study: 25288189

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23219623

Group type: EXPERIMENTAL
Intervention: RHA press‐fit cobalt‐chromium cup
Number of subjects: 71

Group type: COMPARATOR
Intervention: THA with a threaded titanium cup and polyethylene‐metal‐inlay insert
Number of subjects: 71
Study: 21788757

Group type: EXPERIMENTAL
Intervention: zinc-ORS
Number of subjects: 500

Group type: COMPARATOR
Intervention: ORS
Number of subjects: 500
Study: 19512972

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 57
Study: 16458629

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 14754707

Group type: EXPERIMENTAL
Intervention: Lidocaine plus naproxen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Naproxen only
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11776671

Group type: EXPERIMENTAL
Intervention: Ambulatory laparoscopic cholecystectomy (AM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Overnight stay laparoscopic cholecystectomy (OS)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (AM and OS)
Number of subjects: 86
Study: 9256142

Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream applied to the painful site four times daily for 8 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo cream applied to the painful site four times daily for 8 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 99
Study: 8509640

Group type: COMPARATOR
Intervention: Recombinant IFN alpha‐2b alone (5 MU s.c. thrice weekly for 5 months)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of IFN alpha‐2b and recombinant IL‐2 (3 MU IFN alpha‐2b s.c. thrice weekly for 5 months, with IL-2 added starting at month 2)
Number of subjects: 37
Study: 31340972

Group type: EXPERIMENTAL
Intervention: Baseline data model
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Baseline/6-week data model
Number of subjects: 618
Study: 27888093

Group type: EXPERIMENTAL
Intervention: rATG/Daclizumab
Number of subjects: 200

Group type: COMPARATOR
Intervention: rATG/Alemtuzumab
Number of subjects: 200
Study: 26790205

Group type: EXPERIMENTAL
Intervention: Deep-layer embedding group (multifidus muscle layer)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Middle-layer embedding group (semispinalis capitis muscle layer)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shallow-layer embedding group (subcutaneous layer)
Number of subjects: 90
Study: 23636088

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through midmedial portal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through midlateral portal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intra-articular injection through superolateral portal
Number of subjects: 120
Study: 22117660

Group type: EXPERIMENTAL
Intervention: FRESH START intervention (tailored mailed print materials promoting fruit and vegetable consumption, reduced total and saturated fat intake, and/or increased exercise)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Standardized mailed materials (control group)
Number of subjects: 543
Study: 18561010

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study: 16855169

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice/weekly) and Infliximab (3 mg/kg on 0, 2, 6, and every 8 weeks thereafter)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (stable therapy with prednisone and MTX without anti-TNF-alpha therapy)
Number of subjects: 30
Study: 12623939

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg once daily
Number of subjects: 6311

Group type: COMPARATOR
Intervention: Co‐amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily
Number of subjects: 6311
Study: 11180916

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1alpha hydroxyvitamin D3, 0.75 microg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone, 45 mg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus Vitamin K2
Number of subjects: 92

Group type: COMPARATOR
Intervention: Calcium (calcium lactate, 2 g/day)
Number of subjects: 92
Study: 9084066

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 8451526

Group type: EXPERIMENTAL
Intervention: STATIC
Number of subjects: 20

Group type: COMPARATOR
Intervention: BALLISTIC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 20
Study: 3612353

Group type: EXPERIMENTAL
Intervention: Surgical insertion
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Percutaneous insertion
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both techniques (surgical and percutaneous)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Duration of circulatory support
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vascular complications
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Deaths related to circulatory assistance (percutaneous group)
Number of subjects: 102
Study: 31820012

Group type: EXPERIMENTAL
Intervention: Single-blind peer review
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind peer review
Number of subjects: 0
Study: 29863955

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus chemotherapy (ABCP)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Bevacizumab plus carboplatin plus paclitaxel (BCP)
Number of subjects: 692
Study: 27646624

Group type: EXPERIMENTAL
Intervention: Saebo‐Flex™ device
Number of subjects: 9

Group type: COMPARATOR
Intervention: Usual rehabilitation (task-specific motor training)
Number of subjects: 9
Study: 24811564

Group type: EXPERIMENTAL
Intervention: Blood donors who completed the screening questionnaire
Number of subjects: 854

Group type: COMPARATOR
Intervention: Blood donors who did not complete the screening questionnaire
Number of subjects: 854
Study: 24106570

Group type: EXPERIMENTAL
Intervention: Surgery (intramedullary nailing)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Skeletal traction
Number of subjects: 148
Study: 20712245

Group type: EXPERIMENTAL
Intervention: Psychological gender—masculinity dimension
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anxiety (as a state and as a feature)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Coping with stress
Number of subjects: 37
Study: 17437819

Group type: EXPERIMENTAL
Intervention: Adjuvant weekly docetaxel (35 mg/m² weekly for 6 cycles, starting 4 to 12 weeks post-surgery)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Adjuvant weekly docetaxel
Number of subjects: 77
Study: 15554993

Group type: EXPERIMENTAL
Intervention: 170 degrees wide-angle colonoscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 140 degrees angle of view colonoscope
Number of subjects: 50
Study: 11728297

Group type: EXPERIMENTAL
Intervention: Pressure- and volume-limited ventilation according to the ARDS Network protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open lung approach to mechanical ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids in the late phase of ARDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up of ARDS survivors
Number of subjects: 0
Study: 9563867

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 microg/kg + Glycopyrronium 8 microg/kg (Ne-Glyc)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 microg/kg + Atropine 20 microg/kg (Ne-Atr)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Edrophonium 200 microg/kg + Atropine 300 microg (Edr-Atr (1))
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Edrophonium 500 microg/kg + Atropine 7 microg/kg (Edr-Atr (2))
Number of subjects: 84
Study: 8555574

Group type: EXPERIMENTAL
Intervention: Centri-Safe valve (experimental group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no valve)
Number of subjects: 24
Study: 3323130

Group type: EXPERIMENTAL
Intervention: Trazodone (23 patients)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amitriptyline (22 patients)
Number of subjects: 45
Study: 31562412

Group type: EXPERIMENTAL
Intervention: Clinpro 5000
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clinpro Tooth Crème
Number of subjects: 120

Group type: COMPARATOR
Intervention: MI Paste Plus
Number of subjects: 120
Study: 30403369

Group type: EXPERIMENTAL
Intervention: UCL reconstruction with docking technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: UCL repair augmented with internal bracing
Number of subjects: 18
Study: 27610820

Group type: EXPERIMENTAL
Intervention: Reduced-iodine-dose dual-energy CTA (21-27 g I)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard-iodine-dose single-energy CTA (30-37 g I)
Number of subjects: 66
Study: 24467257

Group type: EXPERIMENTAL
Intervention: Tobacco treatment intervention
Number of subjects: 693
Study: 22088576

Group type: EXPERIMENTAL
Intervention: Gentamicin 320 μg/mL in 4% sodium citrate
Number of subjects: 303

Group type: COMPARATOR
Intervention: Heparin 1,000 U/mL
Number of subjects: 303
Study: 20632509

Group type: EXPERIMENTAL
Intervention: VSD combined with flaps
Number of subjects: 15

Group type: COMPARATOR
Intervention: Only flaps (non-VSD group)
Number of subjects: 15
Study: 17673094

Group type: COMPARATOR
Intervention: Cue group (encouraging discussion)
Number of subjects: 250

Group type: COMPARATOR
Intervention: PtEd group (patient education handout)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Control group (standard handout)
Number of subjects: 250
Study: 15750150

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 18F-FLT PET
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of 18F-FDG PET and 18F-FLT PET
Number of subjects: 10
Study: 22276283

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP; 2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP; 8 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP/NX; 2 mg buprenorphine + 0.5 mg naloxone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP/NX; 8 mg buprenorphine + 2 mg naloxone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP/NX)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) and Buprenorphine/Naloxone (BUP/NX)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10609378

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (anticoagulants)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Postoperative duplex scan on the 5th postoperative day
Number of subjects: 190
Study: 7740337

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 229
Study: 1789091

Group type: EXPERIMENTAL
Intervention: Polymetacrylate (PMMA) lens
Number of subjects: 59

Group type: COMPARATOR
Intervention: Soft hydrogel (IO-gel) lens
Number of subjects: 59
Study: 7261900

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 34
Study: 30535977

Group type: EXPERIMENTAL
Intervention: Modified method of local infiltration (MMLI) during endoscopic stapes surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Microscopic approach
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MMLI
Number of subjects: 70
Study: 28885054

Group type: EXPERIMENTAL
Intervention: Zephyr endobronchial valve (EBV) treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 97
Study: 26342738

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23344273

Group type: EXPERIMENTAL
Intervention: Immediate oxytocin infusion
Number of subjects: 190

Group type: COMPARATOR
Intervention: Delayed oxytocin infusion (4 hours)
Number of subjects: 190
Study: 21214631

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical vehicle
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical calcipotriol/betamethasone dipropionate (C/B)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15)
Number of subjects: 730
Study: 19707226

Group type: EXPERIMENTAL
Intervention: High-Glycemic Index (HGI) diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-Glycemic Index (LGI) diet
Number of subjects: 8
Study: 18260869

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10.8 +/- 0.1 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 101
Study: 15380903

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sunflower oil (SO)
Number of subjects: 31
Study: 11380321

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Triple therapy (metronidazole, amoxicillin, bismuth subsalicylate for 2 weeks, followed by bismuth alone for 14 weeks)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Triple therapy and calcium carbonate
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 9661650

Group type: EXPERIMENTAL
Intervention: Leucine 54 (L) polymorphism
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Genotype L/L
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Gln-Arg 192 polymorphism
Number of subjects: 199
Study: 7710452

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPR) 60 mg/m2 administered as an i.v. bolus over 2 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPR) 60 mg/m2 with interferon-alpha-2b (IFN) 5 x 10(6) IU s.c. 3 times a week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epirubicin (EPR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPR) with interferon-alpha-2b (IFN)
Number of subjects: 10
Study: 2196493

Group type: COMPARATOR
Intervention: External tocography
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Internal tocography
Number of subjects: 250
Study: 518264

Group type: EXPERIMENTAL
Intervention: Interval cycle training (5 days a week for 8 weeks, 4 bouts of 4 minutes each with 3-minute recovery, heart rates 170-195)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional sports-oriented physical education (control group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 32
Study: 31972236

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 205
Study: 30707756

Group type: EXPERIMENTAL
Intervention: YWI (educational intervention)
Number of subjects: 467

Group type: COMPARATOR
Intervention: PAI (contact time control physical activity intervention)
Number of subjects: 467
Study: 28135150

Group type: EXPERIMENTAL
Intervention: High-dose interferon α-2b at 20 MU/m2/d IV for 5 days every week for 4 weeks
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: High-dose interferon α-2b
Number of subjects: 1150
Study: 25915670

Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional hemostasis
Number of subjects: 10
Study: 23474589

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 103
Study: 20103970

Group type: EXPERIMENTAL
Intervention: Abciximab-coated stent
Number of subjects: 188

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 188
Study: 18179609

Group type: EXPERIMENTAL
Intervention: Itopride (200 mg t.i.d. for 7 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16643825

Group type: EXPERIMENTAL
Intervention: Temporizing management
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 216
Study: 12649510

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration with urokinase instilled via catheter over 48 hours (6-hour intervals)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nonsurgical treatment (control group)
Number of subjects: 71
Study: 11142421

Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (MAP)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: High α-fetoprotein (AFP) levels
Number of subjects: 542

Group type: COMPARATOR
Intervention: Diagnosed preeclampsia
Number of subjects: 542

Group type: COMPARATOR
Intervention: Hypertension of pregnancy
Number of subjects: 542
Study: 8692311

Group type: EXPERIMENTAL
Intervention: D2 resection surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: D(1) resection surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surgical protocols and standards developed in the trial
Number of subjects: 80
Study: 2058589

Group type: EXPERIMENTAL
Intervention: Atole (moderate energy supplement)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fresco (low energy supplement)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-Atole group (consumed >= 10% of daily RDI from supplement)
Number of subjects: 4

Group type: COMPARATOR
Intervention: High-Fresco group (low supplemental energy intake)
Number of subjects: 4
Study: 6202387

Group type: EXPERIMENTAL
Intervention: Concurrent immunotherapy with the methanol extraction residue of bacillus Calmette‐Guerin (MER)
Number of subjects: 204

Group type: COMPARATOR
Intervention: 5‐fluorouracil and methyl‐CCNU
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MER
Number of subjects: 204
Study: 31539073

Group type: EXPERIMENTAL
Intervention: RightRx intervention (electronic medication reconciliation)
Number of subjects: 3491
Study: 29413138

Group type: EXPERIMENTAL
Intervention: Video-Feedback Therapy (VFT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 144
Study: 26624973

Group type: COMPARATOR
Intervention: Filtered back projection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adaptive statistical iterative reconstruction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Model-based iterative reconstruction (MBIR)
Number of subjects: 20
Study: 24229346

Group type: EXPERIMENTAL
Intervention: Positive psychology intervention program (training based on autobiographical memory, forgiveness, and gratitude)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study: 22114904

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) 400 mg daily for 5 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metronidazole (MTZ) 250 mg t.i.d. for 5 days
Number of subjects: 150
Study: 20391892

Group type: EXPERIMENTAL
Intervention: 30 minutes of practice viewing 360 pictures of skin lesions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Viewing a skin cancer pamphlet for 5 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: No practice or practice with a filler task
Number of subjects: 100
Study: 17679560

Group type: EXPERIMENTAL
Intervention: Light tower
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Light visor
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Litebook
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LED spectacles
Number of subjects: 14

Group type: COMPARATOR
Intervention: No phototherapy control
Number of subjects: 14
Study: 17874889

Group type: EXPERIMENTAL
Intervention: Contracting, prompting, and reinforcing (CPR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 150
Study: 15853564

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no lipid-lowering therapy)
Number of subjects: 0
Study: 11197057

Group type: EXPERIMENTAL
Intervention: High protein diet (37:50:28, carbohydrate:protein:fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Balanced 5:1 carbohydrate:protein diet (105:21:11)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High carbohydrate diet (126:10:6)
Number of subjects: 8
Study: 9184602

Group type: EXPERIMENTAL
Intervention: 1 year treatment (group I)
Number of subjects: 161

Group type: COMPARATOR
Intervention: 3 years treatment (group II)
Number of subjects: 161
Study: 8267059

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 50 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All ethinyl estradiol groups combined
Number of subjects: 33

Group type: COMPARATOR
Intervention: Norethindrone 1 mg alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol plus norethindrone
Number of subjects: 33